BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 98

Insulin Drug Delivery Development Drugs 98

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Drug Discovery World

NOVEMBER 1, 2023

Previous spaceflight investigations indicate that growing crystals in space could yield a more uniform product with fewer imperfections, which can improve the drug discovery and development process. The post First spaceflight mission for drug development lab appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Insulin Branding 59

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Sales 98

pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59

Insulin Trials Development Drugs 59

Drug Channels

JANUARY 9, 2024

For 2024, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again each excluded 600 or more drugs from their standard formularies. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Insulin 89

Insulin Pharmacy Drugs Production 89

Bio Pharma Dive

JULY 14, 2021

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap.

Insulin 286

Insulin Development Drugs 286

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Buy the report here.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Drug Channels

APRIL 3, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. There are also unusual formulary developments for insulin products, many of which experienced massive list price cuts for 2024. You can find our updated counting below.

Insulin 52

Insulin Pharmacy Drugs Production 52

pharmaphorum

JANUARY 25, 2023

The 501(c)3 non-profit Tidepool, which seeks to empower the next generation of innovations in diabetes management, has announced that the US Food and Drug Administration (FDA) has cleared Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in those six years old and above.

Insulin 59

Insulin Development Drugs Research 59

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. The initial therapeutic focus is diabetes, with three insulin-based products in development.

Insulin 52

Insulin Production Marketing Pharma Companies 52

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

XTalks

OCTOBER 13, 2021

Researchers at the University of Toledo have developed a vaccine against inflammatory arthritis that has shown promise in animal models. The potential cybersecurity risk associated with the remote controllers could under- or over-deliver insulin to patients if an unauthorized user hacks into the system.

Insulin 59

Insulin Life Science Vaccination Vaccine 59

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

Drug Discovery World

FEBRUARY 23, 2024

In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The post This week in drug discovery (19-23 February) appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Insulin FDA Approval Drugs 52

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Developed for oral use, Galvus can be used as an adjunct to diet and exercise to enhance glycemic control in type 2 diabetes mellitus patients.

Branding 130

Branding Insulin Drugs Production 130

XTalks

FEBRUARY 2, 2023

The US Food and Drug Administration (FDA) has recently cleared for marketing an app called Tidepool Loop which can be used with compatible devices for automated insulin dosing (AID). The Tidepool loop app involves three integral parts: an integrated continuous glucose monitor (iCGM), a controller and an insulin pump.

Insulin 52

Insulin Marketing Life Science Development 52

pharmaphorum

MAY 16, 2022

Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check. The drug is injected under the skin once a week and the dose can be adjusted to meet an individual’s blood sugar needs. more than insulin degludec and 1.0%

FDA Approval 115

FDA Approval Insulin Drugs Hormones 115

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Drug Discovery World

NOVEMBER 14, 2022

Alternative to insulin. Early-stage biopharma company Atrogi initiated a Phase I study for its drug candidate ATR-258 targeting type 2 diabetes in Germany, which is expected to announce results at the end of the year. . Find out more: Collaboration to develop AAV vectors for diabetes gene therapy .

Development 52

Development Gene Therapy Drugs Gene 52

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

Pharmaceutical Technology

JUNE 29, 2022

The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale. Developing best-in-class speciality enzymes. Meanwhile, the pharma industry is undergoing somewhat of a transformation itself.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

XTalks

NOVEMBER 22, 2022

Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

Drug Discovery World

JANUARY 31, 2024

The treatment decision followed previous case reports where adult patients with breast cancer, being treated with the same drug, were shown to have experienced high blood glucose profile. The medication regulates cell growth, proliferation and development and insulin signalling.

Drugs 52

Drugs Insulin Medicine Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2021

and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions.

Insulin 40

Insulin Medicine Hormones Development 40

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare.

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

STAT News

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Insulin 96

Insulin Pharmacy Pharma Companies Production 96

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

pharmaphorum

NOVEMBER 21, 2022

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D. It also has an option on global marketing rights to the drug.

Drugs 116

Drugs Insulin FDA Approval Sales 116

Drug Discovery World

JULY 7, 2023

It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial of datopotamab deruxtecan did not meet its second primary endpoint and saw an 8% drop in its stock market value as a result. The post This week in drug discovery (3-7 July) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs FDA Approval Insulin Gene 52

Pharmaceutical Technology

MARCH 29, 2023

Evotec and Bristol Myers Squibb have extended and expanded their strategic partnership to develop a broadened neurodegenerative diseases programme pipeline. The partnership pursues an innovative approach to discovering and developing new medicines, using many of the modality-agnostic precision medicine platforms of Evotec.

Clinical Trials 130

Clinical Trials Clinical Trials Insulin Medicine 130

BioPharma Reporter

AUGUST 30, 2021

A new type of self-injecting capsule could deliver medications at comparable levels to those given via injection, according to a preclinical study.

Insulin 105

Insulin Antibody Drugs Development 105

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. In 2023, there will be opportunities for a wider range of CMOs that can offer services for less innovative drugs requiring reformulation or biosimilar production.

Drugs 130

Drugs Manufacturing Contract Manufacturing FDA Approval 130

pharmaphorum

JULY 7, 2021

Three months ago, the FDA said it was unconvinced by a bridging study designed to show equivalence between Provention’s product intended for commercial sale, made by contract manufacturer AGC Biologics, and the drug that teplizumab’s original developer Eli Lilly used in clinical trials.

Drugs 98

Drugs Insulin Contract Manufacturing Antibody 98

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells.

Development 40

Development Insulin Drugs Clinical Trials 40